140 related articles for article (PubMed ID: 11129739)
1. Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity.
Zhang ZW; Patchett SE; Farthing MJ
Anticancer Drugs; 2000 Oct; 11(9):757-64. PubMed ID: 11129739
[TBL] [Abstract][Full Text] [Related]
2. Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
Deptala A; Li X; Bedner E; Cheng W; Traganos F; Darzynkiewicz Z
Int J Oncol; 1999 Nov; 15(5):861-71. PubMed ID: 10536167
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of gastric cancer by camptothecin involves apoptosis and multiple cellular pathways.
Litvak DA; Papaconstantinou HT; Hwang KO; Kim M; Evers BM; Townsend CM
Surgery; 1999 Aug; 126(2):223-30. PubMed ID: 10455888
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
Gupta M; Fan S; Zhan Q; Kohn KW; O'Connor PM; Pommier Y
Clin Cancer Res; 1997 Sep; 3(9):1653-60. PubMed ID: 9815856
[TBL] [Abstract][Full Text] [Related]
5. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
McDonald AC; Brown R
Br J Cancer; 1998 Sep; 78(6):745-51. PubMed ID: 9743293
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.
Liu W; Zhang R
Int J Oncol; 1998 Apr; 12(4):793-804. PubMed ID: 9499438
[TBL] [Abstract][Full Text] [Related]
7. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
8. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function.
Shao RG; Cao CX; Shimizu T; O'Connor PM; Kohn KW; Pommier Y
Cancer Res; 1997 Sep; 57(18):4029-35. PubMed ID: 9307289
[TBL] [Abstract][Full Text] [Related]
9. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.
Wang Y; Zhu S; Cloughesy TF; Liau LM; Mischel PS
Oncogene; 2004 Feb; 23(6):1283-90. PubMed ID: 14961077
[TBL] [Abstract][Full Text] [Related]
10. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells.
Jiang XH; Wong BC; Lin MC; Zhu GH; Kung HF; Jiang SH; Yang D; Lam SK
Oncogene; 2001 Nov; 20(55):8009-18. PubMed ID: 11753684
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of proteasome function induced apoptosis in gastric cancer.
Fan XM; Wong BC; Wang WP; Zhou XM; Cho CH; Yuen ST; Leung SY; Lin MC; Kung HF; Lam SK
Int J Cancer; 2001 Aug; 93(4):481-8. PubMed ID: 11477551
[TBL] [Abstract][Full Text] [Related]
12. UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells.
Jones CB; Clements MK; Redkar A; Daoud SS
Int J Oncol; 2000 Nov; 17(5):1043-51. PubMed ID: 11029511
[TBL] [Abstract][Full Text] [Related]
13. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
14. Bromodeoxyuridine induces p53-dependent and -independent cell cycle arrests in human gastric carcinoma cell lines.
Peng DF; Sugihara H; Hattori T
Pathobiology; 2001; 69(2):77-85. PubMed ID: 11752901
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines.
te Poele RH; Joel SP
Br J Cancer; 1999 Dec; 81(8):1285-93. PubMed ID: 10604724
[TBL] [Abstract][Full Text] [Related]
16. Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions.
Scovassi AL; Pellegata NS; Di Stefano L; Padovan L; Negri C; Prosperi E; Riva F; Ciomei M; Ranzani GN
Anticancer Res; 2001; 21(4A):2803-8. PubMed ID: 11724358
[TBL] [Abstract][Full Text] [Related]
17. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
[TBL] [Abstract][Full Text] [Related]
18. Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells.
Arah IN; Song K; Seth P; Cowan KH; Sinha BK
Anticancer Res; 1998; 18(3A):1845-9. PubMed ID: 9673414
[TBL] [Abstract][Full Text] [Related]
19. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
Jones CB; Clements MK; Wasi S; Daoud SS
Cancer Chemother Pharmacol; 1997; 40(6):475-83. PubMed ID: 9332461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
